171 related articles for article (PubMed ID: 32048272)
1. Fibrin lysability is associated with central obesity and inflammation in women with polycystic ovary syndrome.
Godtfredsen ACM; Sidelmann JJ; Gram JB; Andersen M; Glintborg D
Acta Obstet Gynecol Scand; 2020 Aug; 99(8):1078-1084. PubMed ID: 32048272
[TBL] [Abstract][Full Text] [Related]
2. Android fat distribution affects some hemostatic parameters in women with polycystic ovary syndrome compared with healthy control subjects matched for age and body mass index.
de Mendonça-Louzeiro MR; Annichino-Bizzacchi JM; Benetti-Pinto CL
Fertil Steril; 2015 Aug; 104(2):467-73. PubMed ID: 26051101
[TBL] [Abstract][Full Text] [Related]
3. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome.
Mannerås-Holm L; Baghaei F; Holm G; Janson PO; Ohlsson C; Lönn M; Stener-Victorin E
J Clin Endocrinol Metab; 2011 Apr; 96(4):1068-76. PubMed ID: 21252248
[TBL] [Abstract][Full Text] [Related]
4. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
Oral B; Mermi B; Dilek M; Alanoğlu G; Sütçü R
Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
[TBL] [Abstract][Full Text] [Related]
5. Polycystic ovary syndrome: cardiovascular risk factors according to specific phenotypes.
Aziz M; Sidelmann JJ; Faber J; Wissing ML; Naver KV; Mikkelsen AL; Nilas L; Skouby SO
Acta Obstet Gynecol Scand; 2015 Oct; 94(10):1082-9. PubMed ID: 26123797
[TBL] [Abstract][Full Text] [Related]
6. Fibrinolytic Changes in Women with Preeclampsia.
Godtfredsen AC; Sidelmann JJ; Dolleris BB; Jørgensen JS; Johansen EKJ; Pedersen MFB; Palarasah Y; Gram JB
Clin Appl Thromb Hemost; 2022; 28():10760296221126172. PubMed ID: 36217728
[TBL] [Abstract][Full Text] [Related]
7. Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
Güldaş M; Altinkaya SÖ; Nergiz S; Demircan-Sezer S; Yüksel H
Gynecol Endocrinol; 2015 Jul; 31(7):536-9. PubMed ID: 26220768
[TBL] [Abstract][Full Text] [Related]
8. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome.
Erdoğan M; Karadeniz M; Alper GE; Tamsel S; Uluer H; Cağlayan O; Saygili F; Yilmaz C
Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):143-7. PubMed ID: 18350479
[TBL] [Abstract][Full Text] [Related]
9. Evidence of proatherogenic inflammation in polycystic ovary syndrome.
González F; Rote NS; Minium J; Kirwan JP
Metabolism; 2009 Jul; 58(7):954-62. PubMed ID: 19375763
[TBL] [Abstract][Full Text] [Related]
10. Coagulation factor dysregulation in polycystic ovary syndrome is an epiphenomenon of obesity.
Moin ASM; Sathyapalan T; Butler AE; Atkin SL
Clin Endocrinol (Oxf); 2023 Jun; 98(6):796-802. PubMed ID: 36859809
[TBL] [Abstract][Full Text] [Related]
11. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
[TBL] [Abstract][Full Text] [Related]
12. Comparison of regional fat mass measurement by whole body DXA scans and anthropometric measures to predict insulin resistance in women with polycystic ovary syndrome and controls.
Glintborg D; Petersen MH; Ravn P; Hermann AP; Andersen M
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1235-1243. PubMed ID: 27529295
[TBL] [Abstract][Full Text] [Related]
13. The polycystic ovary syndrome per se is not associated with increased chronic inflammation.
Möhlig M; Spranger J; Osterhoff M; Ristow M; Pfeiffer AF; Schill T; Schlösser HW; Brabant G; Schöfl C
Eur J Endocrinol; 2004 Apr; 150(4):525-32. PubMed ID: 15080783
[TBL] [Abstract][Full Text] [Related]
14. Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.
Durmus U; Duran C; Ecirli S
J Endocrinol Invest; 2017 May; 40(5):487-497. PubMed ID: 27838846
[TBL] [Abstract][Full Text] [Related]
15. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome.
Verit FF
Arch Gynecol Obstet; 2010 Jun; 281(6):1009-14. PubMed ID: 19771438
[TBL] [Abstract][Full Text] [Related]
16. Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives.
Glintborg D; Sidelmann JJ; Altinok ML; Mumm H; Andersen M
Metabolism; 2015 Oct; 64(10):1272-8. PubMed ID: 26194691
[TBL] [Abstract][Full Text] [Related]
17. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.
Holte J; Bergh T; Gennarelli G; Wide L
Clin Endocrinol (Oxf); 1994 Oct; 41(4):473-81. PubMed ID: 7955458
[TBL] [Abstract][Full Text] [Related]
18. Impact of interlukin-6 on central obesity measures in women with polycystic ovarian syndrome.
Alissa EM; Algarni SA; Khaffji AJ; Al Mansouri NM
J Obstet Gynaecol; 2020 Nov; 40(8):1133-1137. PubMed ID: 32157932
[TBL] [Abstract][Full Text] [Related]
19. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.
Kurek Eken M; Sahin Ersoy G; Yayla Abide C; Sanverdi İ; Devranoglu B; Kutlu T; Çevik Ö
J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233
[TBL] [Abstract][Full Text] [Related]
20. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome.
Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C
Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
